Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial JW Murrough, DV Iosifescu, LC Chang, RK Al Jurdi, CE Green, AM Perez, ... American Journal of Psychiatry 170 (10), 1134-1142, 2013 | 1400 | 2013 |
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression JW Murrough, AM Perez, S Pillemer, J Stern, MK Parides, M aan het Rot, ... Biological psychiatry 74 (4), 250-256, 2013 | 818 | 2013 |
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression RB Price, MK Nock, DS Charney, SJ Mathew Biological psychiatry 66 (5), 522-526, 2009 | 751 | 2009 |
The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis ST Wilkinson, ED Ballard, MH Bloch, SJ Mathew, JW Murrough, A Feder, ... American journal of psychiatry 175 (2), 150-158, 2018 | 691 | 2018 |
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression M Aan Het Rot, KA Collins, JW Murrough, AM Perez, DL Reich, ... Biological psychiatry 67 (2), 139-145, 2010 | 589 | 2010 |
A consensus statement on the use of ketamine in the treatment of mood disorders G Sanacora, MA Frye, W McDonald, SJ Mathew, MS Turner, ... JAMA psychiatry 74 (4), 399-405, 2017 | 510 | 2017 |
Neurobiological mechanisms in major depressive disorder M aan het Rot, SJ Mathew, DS Charney Cmaj 180 (3), 305-313, 2009 | 483 | 2009 |
Targeting glutamate signalling in depression: progress and prospects JW Murrough, CG Abdallah, SJ Mathew Nature Reviews Drug Discovery 16 (7), 472-486, 2017 | 461 | 2017 |
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) M Fava, MP Freeman, M Flynn, H Judge, BB Hoeppner, C Cusin, ... Molecular psychiatry 25 (7), 1592-1603, 2020 | 419 | 2020 |
Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment‐resistant depression RB Price, DV Iosifescu, JW Murrough, LC Chang, RK Al Jurdi, SZ Iqbal, ... Depression and anxiety 31 (4), 335-343, 2014 | 392 | 2014 |
Ketamine for depression: where do we go from here? M Aan Het Rot, CA Zarate Jr, DS Charney, SJ Mathew Biological psychiatry 72 (7), 537-547, 2012 | 386 | 2012 |
Novel drugs and therapeutic targets for severe mood disorders SJ Mathew, HK Manji, DS Charney Neuropsychopharmacology 33 (9), 2080-2092, 2008 | 322 | 2008 |
Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder RB Price, DC Shungu, X Mao, P Nestadt, C Kelly, KA Collins, ... Biological psychiatry 65 (9), 792-800, 2009 | 311 | 2009 |
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression CN Haile, JW Murrough, DV Iosifescu, LC Chang, RK Al Jurdi, A Foulkes, ... International Journal of Neuropsychopharmacology 17 (2), 331-336, 2014 | 285 | 2014 |
Ketamine for treatment-resistant unipolar depression: current evidence SJ Mathew, A Shah, K Lapidus, C Clark, N Jarun, B Ostermeyer, ... CNS drugs 26, 189-204, 2012 | 276 | 2012 |
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial SJ Mathew, JW Murrough, M aan het Rot, KA Collins, DL Reich, ... International Journal of Neuropsychopharmacology 13 (1), 71-82, 2010 | 263 | 2010 |
Ketamine safety and tolerability in clinical trials for treatment-resistant depression LB Wan, CF Levitch, AM Perez, JW Brallier, DV Iosifescu, LC Chang, ... The Journal of clinical psychiatry 76 (3), 10121, 2014 | 258 | 2014 |
Neurobiology of anxiety disorders and implications for treatment. A Garakani, SJ Mathew, DS Charney Mount Sinai Journal of Medicine 73 (7), 2006 | 257 | 2006 |
Neurobiological mechanisms of social anxiety disorder SJ Mathew, JD Coplan, JM Gorman American journal of psychiatry 158 (10), 1558-1567, 2001 | 257 | 2001 |
Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology DC Shungu, N Weiduschat, JW Murrough, X Mao, S Pillemer, JP Dyke, ... NMR in Biomedicine 25 (9), 1073-1087, 2012 | 253 | 2012 |